Chiron to Discuss Plans for Phase III Clinical Development of Tifacogin
03 March 2004 - 12:05AM
PR Newswire (US)
Chiron to Discuss Plans for Phase III Clinical Development of
Tifacogin March 18 Conference Call to Cover Trial Design and Timing
of Study EMERYVILLE, Calif., March 2 /PRNewswire-FirstCall/ --
Chiron Corporation today announced that it will discussits upcoming
Phase III trial for tifacogin in patients with severe
community-acquired pneumonia in a conference call on Thursday,
March 18, at 10:00 a.m. EST. Plans to initiate the trial were
announced in October 2003. This educational call will provide the
opportunity to learn more about the target indication, trial design
and timing of the study. To access the live call, log on to
http://www.chiron.com/webcast. Please connect to the website at
least 15 minutes prior to the conference call to ensure adequate
time to download any necessary software. Alternatively, please call
800-374-0907 (U.S., Canada) or 706-643-3367 (international). Replay
is available approximately two hours after the completion of the
call through 11:55 p.m. EST, March 25, 2004. To access the replay,
call 800-642-1687 (U.S., Canada) or 706-645-9291 (international).
The conference ID number is 5900960. About Tifacogin Tifacogin is a
recombinant form of tissue factor pathway inhibitor, or TFPI.
Clinical studies suggest that the expression of tissue factor, a
naturally occurring protein, significantly contributes to blood
clotting and inflammation of the lungs associated with severe
community-acquired pneumonia. Tifacogin interferes with the
activity of tissue factor andmay be an effective treatment. About
Severe Community-Acquired Pneumonia Severe community-acquired
pneumonia is a serious infection of the lungs affecting
approximately 300,000 patients in the United States annually.
Mortality rates for patients admitted to the ICU with severe
community-acquired pneumonia often exceed 30 percent. No drugs are
currently approved for the reduction of mortality in severe
community-acquired pneumonia. Current therapy includes routine
antibiotics and supportive care. About Chiron Chiron Corporation,
headquartered in Emeryville, California, is a global pharmaceutical
company that leverages a diverse business model to develop and
commercialize high-value products that make a difference in
people's lives. The company has a strategic focus on cancer and
infectious disease. Chiron applies its advanced understanding of
the biology of cancer and infectious disease to develop products
from its platforms in proteins, small molecules and vaccines. The
company commercializes its products through three business units:
BioPharmaceuticals, Vaccines and Blood Testing. For more
information about Chiron, visit the company's website at
http://www.chiron.com/. This news release contains forward-looking
statements, including statements regarding product development
initiatives, new product indications and new product marketing,
that involve risks and uncertainties and are subject to change. A
full discussion of the company's operations and financial
condition, including factors that may affect its business and
future prospects, is contained in documents the company has filed
with the SEC, including the form 10-Q for the quarter ended
September 30, 2003, and the form 10-K for the year ended December
31, 2002, and will be contained in all subsequent periodic filings
made with the SEC. These documents identify important factors that
could cause the company's actual performance to differ from current
expectations, including the outcome of clinical trials, regulatory
review and approvals, manufacturing capabilities, intellectual
property protections and defenses, stock-price and interest-rate
volatility, and marketing effectiveness. In particular, there can
be no assurance that Chiron will successfully develop and receive
approval to market new product or achieve market acceptance for
such new products. Consistent with SEC Regulation FD, we do not
undertake an obligation to update the forward-looking information
we are giving today. DATASOURCE: Chiron Corporation CONTACT:
Corporate Communications & Investor Relations for Chiron,
media, +1-510-923-6500, or investors, +1-510-923-2300 Web site:
http://www.chiron.com/
Copyright
Chiron (NASDAQ:CHIR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chiron (NASDAQ:CHIR)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Chiron (MM) (NASDAQ): 0 recent articles
More Chiron (MM) News Articles